Page 6 of 10
PD-L1 positive participants:
The results were available for 49 participants in the feladilimab group and 52 participants in
the placebo group.
How long did the treatment delay the growth or return of the cancer?
The progression free survival (PFS) is measured from the time of randomisation to
treatment until the cancer grows or returns or the participant dies. The median PFS was
calculated in months for each group at the data cut-off.
The results were available for 52 participants in the feladilimab group and 55 participants in
the placebo group.